Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial

B E De Galan; Sophia Zoungas; J Chalmers; Craig Anderson; Carole Dufouil; Avinesh Pillai; M E Cooper; D E Grobbee; M Hackett; P Hamet; S R Heller; Liu Lisheng; Stephen MacMahon; Giuseppe Mancia; B Neal; C Y Pan; A Patel; N Poulter; Florence Travert; M Woodward

doi:10.1007/s00125-009-1484-7

Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial

B E De Galan, Sophia Zoungas, J Chalmers, Craig Anderson, Carole Dufouil, Avinesh Pillai, M E Cooper, D E Grobbee, M Hackett, P Hamet, S R Heller, Liu Lisheng, Stephen MacMahon, Giuseppe Mancia, B Neal, C Y Pan, A Patel, N Poulter, Florence Travert, M Woodward

Research output: Contribution to journal › Article › Research › peer-review

219 Citations (Scopus)

Abstract

The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial

Original language	English
Pages (from-to)	2328 - 2336
Number of pages	9
Journal	Diabetologia
Volume	52
Issue number	11
DOIs	https://doi.org/10.1007/s00125-009-1484-7
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00125-009-1484-7

Cite this

De Galan, B. E., Zoungas, S., Chalmers, J., Anderson, C., Dufouil, C., Pillai, A., Cooper, M. E., Grobbee, D. E., Hackett, M., Hamet, P., Heller, S. R., Lisheng, L., MacMahon, S., Mancia, G., Neal, B., Pan, C. Y., Patel, A., Poulter, N., Travert, F., & Woodward, M. (2009). Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial. Diabetologia, 52(11), 2328 - 2336. https://doi.org/10.1007/s00125-009-1484-7

@article{9faa0cbe14294403aa1109962c51849d,

title = "Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial",

abstract = "The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial",

author = "\{De Galan\}, \{B E\} and Sophia Zoungas and J Chalmers and Craig Anderson and Carole Dufouil and Avinesh Pillai and Cooper, \{M E\} and Grobbee, \{D E\} and M Hackett and P Hamet and Heller, \{S R\} and Liu Lisheng and Stephen MacMahon and Giuseppe Mancia and B Neal and Pan, \{C Y\} and A Patel and N Poulter and Florence Travert and M Woodward",

year = "2009",

doi = "10.1007/s00125-009-1484-7",

language = "English",

volume = "52",

pages = "2328 -- 2336",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer-Verlag London Ltd.",

number = "11",

}

De Galan, BE, Zoungas, S, Chalmers, J, Anderson, C, Dufouil, C, Pillai, A, Cooper, ME, Grobbee, DE, Hackett, M, Hamet, P, Heller, SR, Lisheng, L, MacMahon, S, Mancia, G, Neal, B, Pan, CY, Patel, A, Poulter, N, Travert, F & Woodward, M 2009, 'Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial', Diabetologia, vol. 52, no. 11, pp. 2328 - 2336. https://doi.org/10.1007/s00125-009-1484-7

Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial. / De Galan, B E; Zoungas, Sophia; Chalmers, J et al.
In: Diabetologia, Vol. 52, No. 11, 2009, p. 2328 - 2336.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial

AU - De Galan, B E

AU - Zoungas, Sophia

AU - Chalmers, J

AU - Anderson, Craig

AU - Dufouil, Carole

AU - Pillai, Avinesh

AU - Cooper, M E

AU - Grobbee, D E

AU - Hackett, M

AU - Hamet, P

AU - Heller, S R

AU - Lisheng, Liu

AU - MacMahon, Stephen

AU - Mancia, Giuseppe

AU - Neal, B

AU - Pan, C Y

AU - Patel, A

AU - Poulter, N

AU - Travert, Florence

AU - Woodward, M

PY - 2009

Y1 - 2009

N2 - The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial

AB - The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial

UR - http://www.springerlink.com/content/f850355060j7214t/

U2 - 10.1007/s00125-009-1484-7

DO - 10.1007/s00125-009-1484-7

M3 - Article

SN - 0012-186X

VL - 52

SP - 2328

EP - 2336

JO - Diabetologia

JF - Diabetologia

IS - 11

ER -

De Galan BE, Zoungas S, Chalmers J, Anderson C, Dufouil C, Pillai A et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial. Diabetologia. 2009;52(11):2328 - 2336. doi: 10.1007/s00125-009-1484-7

Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial

Abstract

UN SDGs

Access to Document

Other files and links

Cite this